Ido Laskov1, Laura Drudi1, Marie-Claude Beauchamp1, Amber Yasmeen1, Alex Ferenczy2, Michael Pollak3, Walter H Gotlieb4. 1. Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada. 2. Department of Pathology, McGill University, Montreal, Quebec, Canada. 3. Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada; Department of Oncology, McGill University, Montreal, Quebec, Canada. 4. Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada; Department of Oncology, McGill University, Montreal, Quebec, Canada. Electronic address: walter.gotlieb@mcgill.ca.
Abstract
BACKGROUND: Metformin has been associated with reduced cancer risk. The mechanisms underlying this cancer protective effect remain unknown. METHODS: "Window of opportunity" study of metformin in women with operable endometrial cancer (EC). Eleven newly diagnosed, untreated, non-diabetic patients with EC received metformin 500 mg tid from diagnostic biopsy to surgery. Fasting plasma insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 1 (IGFBP-1) and insulin-like growth factor binding protein 7 (IGFBP-7) measurements were taken before and after metformin treatment. Ki-67, pAMPK, and pS6 immunohistochemistry staining was performed on the endometrial cancer before and after metformin treatment and was compared to a control group of 10 women with EC who did not receive metformin. RESULTS: Metformin was administered for a mean of 36.6 days. None of the patients suffered side effects requiring withdrawal from the study. The study group comprised 8 patients with endometrioid EC, and 3 non-endometrioid EC, with a mean follow-up time of 57 months. Mean plasma insulin (p=0.0005), IGF-1 (p=0.001), and IGFBP-7 (p=0.0098) were significantly reduced after metformin treatment. A clear reduction in ki-67 and pS6 expression was observed by both conventional light microscope analysis and digital image analysis with a significant mean reduction in percentage of cells staining for ki-67 (9.7%, P=0.02) and pS6 (31%, P=0.03). In the non-treated control group expression was similar between the biopsy and the surgical specimens. CONCLUSIONS: This pilot trial presents biological evidence consistent with anti-proliferative effects of metformin in women with EC in the clinical setting.
BACKGROUND:Metformin has been associated with reduced cancer risk. The mechanisms underlying this cancer protective effect remain unknown. METHODS: "Window of opportunity" study of metformin in women with operable endometrial cancer (EC). Eleven newly diagnosed, untreated, non-diabeticpatients with EC received metformin 500 mg tid from diagnostic biopsy to surgery. Fasting plasma insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 1 (IGFBP-1) and insulin-like growth factor binding protein 7 (IGFBP-7) measurements were taken before and after metformin treatment. Ki-67, pAMPK, and pS6 immunohistochemistry staining was performed on the endometrial cancer before and after metformin treatment and was compared to a control group of 10 women with EC who did not receive metformin. RESULTS:Metformin was administered for a mean of 36.6 days. None of the patients suffered side effects requiring withdrawal from the study. The study group comprised 8 patients with endometrioid EC, and 3 non-endometrioid EC, with a mean follow-up time of 57 months. Mean plasma insulin (p=0.0005), IGF-1 (p=0.001), and IGFBP-7 (p=0.0098) were significantly reduced after metformin treatment. A clear reduction in ki-67 and pS6 expression was observed by both conventional light microscope analysis and digital image analysis with a significant mean reduction in percentage of cells staining for ki-67 (9.7%, P=0.02) and pS6 (31%, P=0.03). In the non-treated control group expression was similar between the biopsy and the surgical specimens. CONCLUSIONS: This pilot trial presents biological evidence consistent with anti-proliferative effects of metformin in women with EC in the clinical setting.
Authors: Pamela T Soliman; Qian Zhang; Russell R Broaddus; Shannon N Westin; David Iglesias; Mark F Munsell; Rosemarie Schmandt; Melinda Yates; Lois Ramondetta; Karen H Lu Journal: Gynecol Oncol Date: 2016-10-13 Impact factor: 5.482
Authors: Mike M Nguyen; Jessica A Martinez; Chiu-Hsieh Hsu; Mitchell Sokoloff; Robert S Krouse; Blake A Gibson; Raymond B Nagle; Howard L Parnes; Catherine Cordova; H-H Sherry Chow Journal: Eur J Cancer Prev Date: 2018-11 Impact factor: 2.497
Authors: Jason A Zell; Christine E McLaren; Timothy R Morgan; Michael J Lawson; Sherif Rezk; C Gregory Albers; Wen-Pin Chen; Joseph C Carmichael; Jinah Chung; Ellen Richmond; L M Rodriguez; Eva Szabo; Leslie G Ford; Michael N Pollak; Frank L Meyskens Journal: Cancer Prev Res (Phila) Date: 2019-12-09
Authors: Maria E Goossens; Frank Buntinx; Maurice P Zeegers; J H M Driessen; Marie L De Bruin; Frank De Vries Journal: Br J Clin Pharmacol Date: 2015-10-28 Impact factor: 4.335
Authors: Jessica K Paulus; Christina D Williams; Furha I Cossor; Michael J Kelley; Robert E Martell Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-05 Impact factor: 4.254
Authors: Marta G Novelle; Ahmed Ali; Carlos Diéguez; Michel Bernier; Rafael de Cabo Journal: Cold Spring Harb Perspect Med Date: 2016-03-01 Impact factor: 6.915